November 9, 2009 – Shire plc, the global specialty biopharmaceutical company, today announced the availability of INTUNIV™ (guanfacine) Extended Release Tablets in pharmacies across the United States for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) in children and adolescents ages 6 to 17.
The details can be read here.
No comments:
Post a Comment